On April 12, 2022 Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, reported it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress taking place in Washington D.C. on April 18-21, 2022 (Press release, Celsion, APR 12, 2022, View Source [SID1234612050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Khursheed Anwar, Chief Scientific Officer at Celsion will present the Company’s technology platform during the Cancer and Immunotherapy session, in his presentation entitled: "Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines." Details of the presentation are as follows:

Session: Cancer and Immunotherapy – M4
Location: Liberty Salon I-K
Title: Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines
Presenter: Dr. Khursheed Anwar, Chief Scientific Officer, Celsion
Date: Thursday, April 21, 2022
Time: 12:00 pm Eastern Time

A replay of Dr. Anwar’s presentation along with his slides will be available after his presentation on the investor portion of the Celsion website under Scientific Presentations.